CD3 (Cluster of differentiation 3), originally known as T3, is one of the first groups of human T lymphocyte surface antigens recognized by monoclonal antibodies. It has been reported that antibodies against CD3 could either stimulate T cells to divide or inhibit the progress of effector functions according to the conditions used. It plays an important role in T cell and the CD3 T-cell co-receptor helps to activate the cytotoxic T-Cell and T helper cells. The CD3 molecule is composed of a protein complex and consists of four distinct chains. The complex of mammals contains a CD3γ chain, a CD3δ chain, and two CD3ε chains. All these chains associate with T-cell receptor and the ζ-chain to generate an activation signal in T lymphocytes. CD30, also known as TNFRSF8 (Tumor necrosis factor (TNF) receptor superfamily member 8), Ki-1 or D1S166E, is an approximately 64 kDa type I transmembrane glycoprotein consisting of 595 amino acids. This cell membrane protein is encoded by the chromosome of 1p36.22 and belongs to the tumor necrosis factor receptor (TNFR) superfamily. In malignant lymphoma, it is expressed on the Reed-Sternberg cells of classical Hodgkin's disease, anaplastic large cell lymphoma (ALCL), and so on. CD30 can interact with TRAF2 and TRAF5, mediating the signal transduction that evokes the activation of NF-kappa-B pathway. This receptor functions as a positive regulator of apoptosis, and also shows a limitation of the proliferative potential of autoreactive CD8 effector T cells and protects the body against autoimmunity.